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levels of telomerase activity to the levels of hTR.3 Whereas many cell
lines and tumors had both increased hTR and telomerase activity, we
found that hTR was present in cell lines and tissues that lacked
telomerase activity, indicating that the RNA is not limiting for telom
erase activity, and that the RNA component is not a good predictor of
the presence of enzyme activity.
MATERIALS AND METhODS
Cell Extracts and Telomerase Assays. HEK cells were cultured in
a-MEM and 10% FBS, grown on 15-cm plates, and split 1:4. Human B cells
were cultured in suspension in RPMI containing 10% }@BS.All cultures
contained 0.03% penicillin and streptomycin. Tumor tissue was obtained from
The University of Texas Southwestern Medical Center at Dallas and from
North Shore University Hospital (Manhasset, New York). Cell and tissue
extracts were prepared and assayed using a PCR based telomerase assay
(TRAP) as described previously (4, 21) using a modified (CCCTAA)n â€œCXâ€•
primer.4 The PCR products were run on a 12â€”15% acrylamide gels. In
experiments with cell lines, enzyme activity was quantified by scanning gels
on a Molecular Dynamics Phospholmager, and the radioactivity in each band
of the repeat ladder was determined using ImageQuant software (Molecular
Dynamics). Total activity was expressed as a percentage of that in 293 cell
extracts (positive control) after normalizing for protein content. Extracts were
considered negative if no products were detected after 7 days of exposure.
RNA Preparation and Northern Blots. RNA was isolated from 10@to 108
cultured cells or 50â€”500mg of tissue according to the acid guanidinium
thiocyanate/phenol/chloroform extraction procedure as described by Ausubel
el a!. (22). Briefly, cells were lysed in a denaturing solution of 4 M guanidine
thiocyanate-25 mM sodium citrate (pH 7.0)-0.l M (3-mercaptoethanol-0.5%
Sarkosyl. The lysate was extracted with saturated phenol, chloroform, isoamyl
alcohol, and sodium acetate (pH 4.0), and the RNA was precipitated from the
water phase with isopropyl alcohol or ethanol. The final pellet was resus
pended in diethylpyrocarbonate-treated water. The absorbance at 260 nm was
measured to determine the RNA concentration, assuming that 1 absorbance
unit per ml contains 40 ,xg of RNA. For purifying RNA from tissues, samples
were lysed by Dounce homogenization in the denaturing solution using a
l.5-ml Eppendorf tube with a fitted pestle (Kimble).
RNA was electrophoresed on 1.5% agarose-2.2 Mformaldehyde gels in 20
mM 4-morpholinepropanesulfonic acid (pH 7.0)-8 mM sodium acetate-l nmi
EDTA for4â€”8h at 5 V/cm (110V using a 21-cm gel). The RNA was passively
transferred onto a Nytran maximum strength membrane (Schleicher and
Schuell), and the RNA was covalently attached to the membrane by baking for
1â€”2h at 80Â°C.Blots were probed overnight in Church hybridization solution
[500 mM sodium phosphate (pH 7.2)-l misiEDTA-l% BSA-7% SDS) con
taming 15% formamide. Blots were rinsed 5 times in 2X SSC and 0.1% SDS,
at room temperature, for 5 mm each. One final wash was performed at the
hybridization temperature for 30 rain in SSC containing 0.1% SDS (for
specific details regarding each probe and the concentration of SSC in the last
wash, see below). Blots hybridized with the hTR component gene or ribosomal
55 RNAwereprobedat 65Â°C;blotsprobedwithanoligonucleotidecompli
mentary to the RNase P RNA were probed at 50Â°C.All blots were exposed to
Kodak XAR film at â€”70Â°Cwith an enhancing screen and to a Phospholmager
screen, and were scanned with a Fuji BAS200 Phospholmager. Typical auto
radiographic exposures for all the experiments were as follows: 3â€”10days for
3 The abbreviations used are: hTR, human telomerase RNA; HEK, human embryonic
kidney; PD, population doubling; RNP, ribonucleoprotein.
4 N. Kim, personal communication.
ABSTRACT
Telomerase activity has been detected in many human immortal cell
lines and in tumor tissues, whereas it is generally absent from primary cell
strains and from many tumor adjacent tissue samples. With the recently
cloned human telomerase RNA (hTR), we used Northern analysis to
follow the levels of hTR in primary, precrisis, and immortalized cells. It
was surprising that the amount of hTR was high in cell strains that lacked
telomerase activity, and the levels did not parallel the increases in telo
merase activity, which accompanies immortalization. In addition, al
though the hTR levels were somewhat higher in tumor samples compared
to nontumor tissues, the level of hTR in a variety of different human
tumors did not predict the level of telomerase activity in the tumor. Thus,
whereas hTR was detected in all samples that have telomerase activity, the
presence of the RNA was not a good a predictor of the presence or amount
of telomerase activity.
INTRODUCTION
Chromosomal rearrangements and end associations are ubiquitous
in cancer cells. The loss of telomeres, which normally provide stabil
ity to chromosome ends, may initiate or drive the genomic instability
that results in abnormal chromosomes and unchecked cell growth
(1â€”5).Telomeres are often shorter in tumor tissue than in normal
adjacent tissue (reviewed in Refs. 5, 6). In many immortal organisms
like yeast and Tetrahymena, telomere length is maintained by the
unusual DNA polymerase, called telomerase. Telomerase is a ribonu
cleoprotein polymerase that adds telomeric sequences onto chromo
some ends (7, 8). In humans, telomerase activity is present in the
germline but is not detected in many normal adult tissues (9). The
absence of telomerase may lead to the telomere shortening seen in
somatic tissues in vivo (reviewed in Ref. 10). In contrast to normal
tissues, telomerase activity is found in many human tumors (for
review, see Refs. 6, 11â€”14).Tissue culture models of cell immortal
ization suggest that telomerase-positive cells are selected for at crisis,
and that telomerase is required for the growth of most immortal cells
with short telomeres (14â€”17).Thus, telomerase has been proposed as
a target for cancer chemotherapy (15). In yeast, telomerase RNA is
essential; in cells that are deleted for the RNA component, telomeres
shorten and cells die after 50â€”70divisions (18, 19). In addition,
antisense experiments with the RNA component of human telomerase
indicate that telomerase inhibition may lead to telomere shortening
and cell death in human tumor cell lines (20). To gain insight into the
regulation of telomerase in cell lines and tumors, we compared the
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blots probed with telomerase RNA, 5 h for blots probed with RNase P RNA,
and less than 1 h for blots probed with ribosomal 55 RNA.
Quantitative Analysis of Telomerase RNA Abundance. To control for
loading errors, telomerase RNA was normalized either to the levels of RNase
P or to 55 RNA signals in the same lane. The tumorstudy was performed
blind, with the identity and telomerase activity status of each sample unknown
until after Northern analysis. Quantification of all RNAs was performed using
a Fuji Phospholmager. The RNA signal for each lane was determined by
drawing a rectangle around each RNA band and integrating the signal over the
area. Some of the samples initially analyzed for telomerase activity were found
to have degraded RNA; these samples were omitted from the analysis pre
sented in Fig. 3.
RESULTS
We analyzed telomerase activity and hTR amounts in primary cells
and during immortalization in vitro in cells expressing viral oncop
roteins. HEK cells transfected with 5V40 T-antigen did not express
telomerase activity until the culture went through crisis (15). These
initial studies were done using a conventional telomerase activity
assay. Recently, a more sensitive PCR-based assay was developed (4,
21). To determine whether precrisis cells were telomerase negative by
analysis with this highly sensitive assay, we reanalyzed one T antigen
expressing clone (HA-l) for telomerase activity every 2â€”Spopulation
doublings during the extended lifespan period during and after crisis.
Representative assays are shown in Fig. lA and are summarized in
Table 1. Cell extracts were diluted and analyzed at three different
concentrations to determine the level of telomerase present and to
avoid false negatives due to possible inhibitors of PCR in the extract.
The results confirmed our earlier findings; telomerase activity was not
detectable in the primary cells or in the extended lifespan phase of
growth but was present during crisis and at all points after crisis
(Table 1). Using the PCR-based assay, telomerase activity was de
tected slightly earlier than in the previous study (PD 61 ; Ref. 15). To
determine the hTR levels in these cells before and after crisis, we used
Northern blot analysis. Blots were probed with an hTR probe and then
reprobed with RNase P to normalize the signal to total RNA (Fig. 2).
hTR was present at high levels even in cells that did not have
detectable telomerase activity (Fig. 1A). The increase in hTR abun
dance was only 2-fold from PD 45 to 114 (Table 1), whereas telom
erase activity increased at least 100-fold. This 100-fold estimate is
based on the presence of activity in the most dilute extracts (0.1 @.tg
protein) at PD 114 and absence of activity at PD 45 at all protein
concentrations (10 p.g being the highest). Thus, telomerase RNA was
present in cells that did not contain detectable telomerase activity.
To examine whether the presence of hTR in telomerase-negative
cell strains was a general finding, we analyzed a second model of cell
immortalization. Human B cells infected with EBV analyzed by
conventional telomerase assays showed telomerase activity only after
crisis. We reanalyzed four B-cell clones using the TRAP assay (Fig.
1B) and found at low protein concentration only postcrisis cells were
telomerase positive, while at high concentration three clones of pre
crisis cells were telomerase positive (Table 2). This is consistent with
recent reports indicating that human hematopoietic cells express te
lomerase activity (21, 23â€”25).To estimate the levels of telomerase
activity, we carried out five serial dilutions of the extracts. In the two
postcrisis clones analyzed (B3 and B4), the postcrisis cells had 500â€”
1800-fold higher levels of telomerase activity than the precrisis cells
(Table 2). Northern analysis of RNA from all four clones showed no
significant difference in the levels of hTR pre- and postcrisis (Fig. 2).
Thus, similar to the immortalization of HEK cells, the levels of the
hTR did not parallel the levels of telomerase activity, again suggesting
that the RNA component of telomerase is not the limiting factor for
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Fig. I. Telomerase activity in transformed cells. A, HA-l is a clonal population of HEK cells transformed by SV4O I antigen. Lysates were prepared from cells of different age
(PD) during the extended lifespan (precrisis), at crisis, and after immortalization (postcrisis), and were assayed for telomerase activity by the TRAP method at 0.1, 1.0, and 10 @.sgprotein
per reaction. One-half of each reaction was loaded on the gel for analysis and quantification of enzyme activity. B, B4 and B3 are clonal populations of EBV-transformed B lymphocytes
thatbecomeimmortalaftercrisis,whereasB2populationsremainmortalandceasegrowthat crisis.Cell lysatespreparedat the indicatedPD pre-andpostcrisiswereassayedfor
telomerase activity as in A. Shown is telomerase activity in reactions containing 1 @.tgprotein, one-half of which were loaded on the gel. + , pretreatment of the lysates with RNase.
Low levels of telomerase activity were detected in precrisis B3 and B4 clones when higher concentrations of extract were assayed (see Table 2).
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hTR LEVELS IN CELL LINES AND TUMORS
a Telomerase activity assayed by TRAP. Amounts (p@g) of protein used in each reaction are indicated.
b The RNA component of human telomerase measured by northern analysis.
C HEK, human embryonic kidney cells, untransformed; HAl, HEK cells transformed by SV4O; 293, HEK transformed by adenovirus 5.
d Transformed cells were assayed at different times after transformation (precrisis and crisis cells are mortal, whereas postcrisis cells are immortal).
e MPD, mean population doublings.
I Activity and RNA levels were normalized to 293 cells assayed on same gel.
g The relative amount of human telomerase RNA (hTR) per lane.
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Fig. 2. Telomerase RNA levels in HEK cells
and B cells. Total RNA was made from the differ
ent cell lines, and 20 j.sg of each were analyzed by
Northern blot analysis. All membranes were first
probed with a radiolabeled random primed frag
ment of hTR. Blots were stripped and reprobed
with an end-labeled oligonucleotide complemen
tao' to RNase P as a control for loading. A, North
em blot analysis of HEK cells transfected with
SV4OT antigen. RNA was made from transfected
cells (HAl) precrisis, at the time of crisis, and
postcrisis. Mean population doubling (MPD) refers
to the population-doubling time after transfection
with SV4OI antigen. For controls, nontransfected
HEK cells and 293 cells, an immortalized cell line
derived from HEK cells transformed with adenovi- B
nis, were also analyzed. B, Northern blot analysis . __________________________
of human B cells infected with EBV. RNA was
made from 2 different transfected clones (B3 and
B4) precrisis, at the time of crisis, and postcrisis.
Mean population doubling (MPD) refers to the
population doubling time after infection with EBV.
Cells from the 293 line were also analyzed as a II 4@
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hTR LEVELS IN CELL LINES AND TUMORS
a Telomerase activity assayed by TRAP. Amounts (@xg) of protein used in each reaction are indicated.
I) The RNA component of human telomerase measured by northem analysis.
C B2â€”B5, human B lymphocytes transformed by EBV.
d Transformed cells were assayed at different times after transformation (precrisis and crisis cells are mortal, whereas postcrisis cells are immortal).
e MPD, mean population doublings.
1Activity and RNA levels were normalized to 293 cells assayed on same gel.
gThe relativeamountof humantelomeraseRNA (hTR) per lane.
S ND, not determined.
â€ÑA, not applicable.
To further examine the correlation of telomerase RNA abundance
and activity, we analyzed 2 1 human tumor samples and 5 normal
tissues (Fig. 3). Extracts were made from tumors, and telomerase
activity was measured. Assays were done using 6.0 p.g of protein, and
those extracts that were negative were tested for possible inhibitors
using serial dilutions of the extracts. Telomerase activity was not
detected in the normal tissues analyzed but was detected in most of the
tumor samples [activity levels are designated as 0 for no activity and
1â€”4(1 is the lowest level) in Fig. 3]. The levels of telomerase activity
varied greatly between the different tumors. Northern analysis was
carried out, and the hTR signal quantitated in a blind study on RNA
isolated from all of the tumor samples (Fig. 3). The hTR was detected
in all of the samples analyzed, including the normal tissues that lacked
detectable telomerase activity. The level of hTR was higher in the
tumor samples (median signal 14,017) than in the normal tissue
(median signal 1, 112), although there was a high degree of
variation. In some cases, the level of hTR in a telomerase-positive
tumor was similar to that of telomerase-negative normal tissue (e.g.,
compare samples 10 and 11). Among the tumor samples, the level of
hTR did not reflect the level of telomerase activity detected. Although
some variability may be introduced during the surgical handling of
tumor tissue before extract preparation, we have not found variability
in the time of tissue freezing after removal to significantly affect
telomerase activity levels (2 1). In addition, a recent study on mouse
tumors in which all tissues were handled identically has also found
tumor to tumor variations in both telomerase activity and telomerase
RNA (34). Finally, the data on hTR levels in tumors and normal tissue
are consistent with the study in cell lines that suggest that telomerase
RNA levels do not reflect the level of telomerase activity. Thus,
telomerase RNA is not a good marker for the presence of telomerase
activity in a given tumor.
To compare hTR levels in tumor and normal tissues from matched
samples from the same individual, we analyzed colorectal carcinoma
samples. RNA was extracted from three tumors and adjacent tissue
samples. hTR was present in both the tumors and the adjacent tissue,
although in all cases there was a higher amount in the tumor samples
(Fig. 4). Telomerase activity assays were also done at three different
protein concentrations (6, 0.6, and 0.06 p.g) on each sample. All of the
tumor samples had telomerase activity. One of the three adjacent
samples (sample 55) showed low levels of telomerase activity, and the
other two were telomerase negative (data not shown). Telomerase
activity has been reported previously in tumor adjacent tissues (21)
and may be due to a low percentage of contaminating tumor cells in
the adjacent sample (occult micrometastasis). None of the six extracts
caused inhibition of PCR in control reactions, indicating that the lack
of signal was not due to inhibition of the PCR-based telomerase assay.
Thus, as for the cell lines and the blind tumor study, telomerase RNA
levels did not parallel telomerase activity in human colorectal carci
noma samples.
DISCUSSION
Telomerase activity is up-regulated in a variety of immortal cell
lines and in tumors in both human and mouse (reviewed in Refs. 6, 11,
13, 26). To understand the regulation of telomerase during tumori
genesis, we analyzed the levels of the recently cloned hTR component
during telomerase activation. In both cell lines and in tumors, we
found that hTR levels did not always parallel the level of telomerase
activity. Although there was an increase in the hTR level when tumor
and normal tissues were compared, the amount of telomerase activity
did not always parallel the amount of hTR. The activity and RNA
levels in tumors may vary at the cellular level. Some large tumors that
have little RNA may only express telomerase RNA (and perhaps
activity) in a portion of the cells. This intratumor heterogeneity might
contribute to the variable level of RNA seen in tumors. An in situ
assay will be required to test this hypothesis.
Similar results showing the presence of telomerase RNA in normal
human tissues that are telomerase negative were recently reported
(20). In addition, a lack of correlation between telomerase RNA and
activity was recently found during progression of multistage tumori
genesis in transgenic mice (34). Taken together, these results indicate
that the telomerase RNA component is not a good predictor of
telomerase activity.
The presence of telomerase RNA in cell cultures that lack telo
merase activity suggests that telomerase is regulated at several differ
ent levels. Telomerase RNA was present in EBV- and SV4O T
antigen-expressing cell clones that did not have detectable telomerase
activity. Recent evidence from transgenic mice suggests that viral
oncogenes or their cellular effects may directly up-regulate telomerase
RNA but not telomerase activity (34). Thus, the increase in hTR in the
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Fig. 3. hTR levels in tumor (T) versus normal
(N) tissues. Total RNA was made from different
tissues, and 25 @gof each were analyzed by North
em blot analysis. *, normal tissues tested; other
tissues are from tumors. The graph shows the rel
ative amounts of telomerase RNA (Relative hTR)
in different tumors normalized to the amount of 5 S
RNA. Telomerase activity levels are plotted on the
right as 0 (for no activity) or 1â€”4to indicate the
relative level of telomerase activity detected. Ex
tracts that showed activity at 0.06 @xgwere desig
nated 4 for telomerase activity. Extracts that had
weak activity at higher concentrations (6 @zg)were
designated 1 for weak activity, 2 for strong activity
at 6 @g.or 3 for strong activity at 0.6 @g.
The lack of activity in cells that contain high levels of hTR may be
due to the absence of a protein component of telomerase or to specific
down-regulators of telomerase present in primary cells and tissues
(27). In Tetrahymena, overexpression of telomerase RNA does not
lead to an increase in the steady-state amount of telomerase RNA,
suggesting that the RNA component must be bound by a limiting
factor, possibly the protein components to be stabilized against deg
radation in vivo. (28) Thus, it will be of interest to determine whether
telomerase proteins are present in cells that lack telomerase activity or
whether telomerase RNA is packaged as a RNP in these cells.
















Fig. 4. Northern blot analysis of human colon tumor (T) samples and normal (N)
adjacent tissue from three patients. The Northem blots were probed with hTR and then









Tetrahymena (29) but not yet from human cells; thus, it is not yet
possible to determine whether they are limiting for telomerase activity
in vivo.
Cell fusion experiments between telomerase-positive immortal
cells and telomerase-negative immortal or normal cells have shown
that telomerase activity is down-regulated in at least some cases,
suggesting a trans-repression activity may be present in telomerase
negative cells (27, 30, 31). This trans-acting repression could act
directly on the availability of one or more telomerase polypeptides or
it may represent a direct repressor of the telomerase enzyme activity.
Mixing extracts from telomerase-positive cells with those from telo
merase-negative cells did not inhibit telomerase activity in the
positive extracts (15, 30, 32). Thus, lack of activity is not due to a
simple, diffusible telomerase inhibitor. However, the presence of a
tightly associated specific telomerase inhibitor has not been excluded.
Telomerase activity is commonly found in a variety of cancers (4,
33). Telomere shortening and eventual cell death were seen in yeast
cells deleted for telomerase RNA component and in human cells
expressing antisense RNA (18â€”20).Thus, telomerase appears to be
required for the growth of at least some immortal cell types. This
requirement has raised the possibility that telomerase inhibitors may
â€” hTR be useful in cancer chemotherapy (reviewed in Ref. 13). Understand
ing the details of telomerase activity and component regulation is
important to evaluate the potential of new therapeutic and diagnostic
approaches to cancer.
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